Viracta Therapeutics (VIRX) Appoints Michael Faerm as CFO May 14, 2024 07:01AM
Viracta Therapeutics (VIRX) Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Do Dec 4, 2023 08:31AM
Viracta Therapeutics (VIRX) Approved to Advance to Higher Dosing in Phase 1b/2 Trial of Nana-val Jun 2, 2022 08:32AM